220 related articles for article (PubMed ID: 21733991)
1. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.
Patrick AR; Schousboe JT; Losina E; Solomon DH
J Clin Endocrinol Metab; 2011 Sep; 96(9):2762-70. PubMed ID: 21733991
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
10. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
11. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.
Scotti L; Arfè A; Zambon A; Merlino L; Corrao G
BMJ Open; 2014 Mar; 4(3):e003758. PubMed ID: 24662445
[TBL] [Abstract][Full Text] [Related]
13. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
[TBL] [Abstract][Full Text] [Related]
14. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
Beukelman T; Saag KG; Curtis JR; Kilgore ML; Pisu M
Osteoporos Int; 2010 Sep; 21(9):1573-84. PubMed ID: 19937227
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
17. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
18. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
van Staa TP; Geusens P; Zhang B; Leufkens HG; Boonen A; Cooper C
Rheumatology (Oxford); 2007 Mar; 46(3):460-6. PubMed ID: 16899499
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
[TBL] [Abstract][Full Text] [Related]
20. Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.
Penton H; Hiligsmann M; Harrison M; Reginster JY; Boonen A; Bansback N
Osteoporos Int; 2016 Sep; 27(9):2697-2707. PubMed ID: 27155885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
